1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search
results consecutively by pressing the navigational buttons
(
<
1 of
11
>).
Within the text the search
result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
Gross profit of the Merck Group improved in the first quarter of 2013 by 7.4% to € 2,036 million (Q1 2012: € 1,896 million), resulting in an increase in gross margin to 76.5% (Q1 2012: 74.0%). Both the lower level of inventory write-downs and changes in the product mix resulting from the good sales development of comparatively high-margin biotech products from the Merck Serono division had a noticeably positive effect. Marketing and selling expenses decreased by 3.1% to € 568 million (Q1 2012: € 587 million), mainly as a result of the efficiency improvement measures implemented in the Merck Serono division. By contrast, royalty, license and commission [...]
[...] Research and development –324.1 –302.8 –4.1 –4.9 –36.4 –35.3 –41.3 –37.6 Operating result (EBIT)1 195.2 161.5 11.8 5.7 172.5 132.4 72.3 82.8 Depreciation and amortization 209.8 222.8 2.8 3.0 30.7 30.4 79.1 75.7 Impairment losses 28.3 9.1 – – 0.1 – 0.1 – Other – – –0.1 – – – – – EBITDA1 433.3 393.3 14.4 8.7 203.3 162.8 151.5 158.5 One-time items 29.4 9.7 –0.1 0.7 4.1 0.6 10.4 7.5 EBITDA pre one-time items (Segment result)1 462.7 403.0 14.3 9.4 207.4 163.4 161.9 166.0 EBITDA margin pre one-time items (% of sales)1 31.8 28.4 12.3 8.7 49.2 42.3 24.2 25.4 Net operating assets2 7,920.2 8,020.6 287.3 283.8 1,157.2 1,187.7 6,394.9 [...]
In the first quarter of 2013, the Merck Serono division maintained the strong momentum of the previous quarters. Total revenues increased by 3.5% to € 1,548 million (Q1 2012: € 1,495 million). This reflected robust organic growth of 4.9% and a decline of 1.4% due to changes in foreign exchange rates. The division’s sales rose by 2.6% to € 1,454 million (Q1 2012: € 1,417 million) resulting from organic growth of 4.0% and a negative exchange rate impact of –1.4%. In addition to the division’s two top-selling products, Rebif® for the treatment of multiple sclerosis (MS) as well as the cancer therapy Erbitux®, the diabetes treatment Glucophage® was one [...]
The Consumer Health division reported sales of € 116 million, an increase of 7.9% (Q1 2012: € 108 million). This reflected organic growth of 9.3% and a 1.4% decrease from changes in foreign exchange rates. The healthy organic increase was apparent across all regions, with sales in Europe benefiting particularly from good development of cough & cold treatments as a result of the unusually long winter period. In addition, growth was further stimulated by increased focus on strategic brands, like Bion® and Femibion®. The efficiency improvements Consumer Health initiated last year are well on track and are beginning to generate visible improvements to the [...]
[...] million Q1 – 2013 Q1 – 2012 Change Total revenues 674.5 655.4 2.9% Sales 668.7 652.6 2.5% Operating result (EBIT) 72.3 82.8 –12.7% Margin (% of sales) 10.8% 12.7% EBITDA 151.5 158.5 –4.4% Margin (% of sales) 22.7% 24.3% EBITDA pre one-time items 161.9 166.0 –2.5% Margin (% of sales) 24.2% 25.4% During the first quarter of 2013, the division’s production costs increased 5.2% to € 280 million (Q1 2012: € 266 million), yielding a gross profit of € 395 million (Q1 2012: € 390 million) or 59.1% of sales (Q1 2012: 59.7%). Changes in product mix contributed to this development, as organic sales growth for hardware and services, which bear lower gross [...]
